19.05.2015
Formycon AG DE000A1EWVY8
DGAP-News: Formycon AG: Carsten Brockmeyer belongs to the top 20 most influential people in the Global 'Medicine Maker Power List' 2015
DGAP-News: Formycon AG / Key word(s): Miscellaneous
Formycon AG: Carsten Brockmeyer belongs to the top 20 most influential
people in the Global 'Medicine Maker Power List' 2015
19.05.2015 / 07:49
---------------------------------------------------------------------
Munich - Carsten Brockmeyer, CEO of Formycon AG, has been ranked No. 12 on
"The Medicine Maker Power List" 2015, an index of the 100 most influential
people across the globe in the field of medicine.
He appears on the list alongside global leaders from the industry,
including CEOs, Nobel Prize winners, and many other celebrated scientists
from the pharmaceutical world. The list also includes names like Prof.
David Baltimore, Nobel Prize winner in Physiology; Robert A. Bradway,
Chairman & CEO, Amgen; Joseph Jimenez, CEO Novartis; Ian C. Read, Chairman,
Pfizer; Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon;
Pascal Soriot, CEO, AstraZeneca; and many more. Carsten Brockmeyer is the
only Germany based business leader on the list.
"I am very glad to be part of this prestigious list of medicine makers, it
is also a great recognition for the important role biosimilars have in the
global access to medicine. I also like to thank the Formycon team for their
commitment to develop global quality biosimilars", says Carsten Brockmeyer.
The Medicine Maker is a UK based publication that is distributed worldwide
to industry professionals. The power list has been compiled from reader
nominations with the help of expert judges and is based entirely on merit.
It was developed in three stages. In stage one, The Medicine Maker invited
readers to nominate those who they thought deserved recognition. In stage
two, a jury of four noted medicine makers selected their top 100 from the
slate of nominees: the results were consolidated into a list of 100 names.
In the final stage, the jury ranked the list, and the average rankings were
combined to provide the final Power List. The list can be accessed here:
https://themedicinemaker.com/the-power-list-2015/
About Formycon:
Formycon AG is a leading independent developer of biosimilars for global
marketing and has become a recognized innovator in the field. The team of
the company which has today become Formycon AG has extensive experience in
the development of complex molecules. The company has already successfully
licensed two protein-based product portfolios out to major pharmaceutical
companies - in 2008 and 2011. Its specialist expertise allows the company
to develop high-quality biosimilars that meet the strict requirements of
the regulatory authorities in highly regulated countries and regions such
as Europe and the USA. Formycon currently has three biosimilar candidates
under development, the first of which has already been licensed out to
Santo Holding GmbH, with further product development projects in the
pipeline. Its aim is to be the first company in the world to present
clinical data for each respective product candidate and on this basis to
license these products out to major pharmaceutical and generics companies
for further development. Alternatively, Formycon offers further development
of its biosimilars all the way through to marketing authorization, as well
as commercial production on behalf of its licensees.
Contact:
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg
Germany
phone +49 (0) 89 - 86 46 67 100
fax + 49 (0) 89 - 86 46 67 110
[email protected] // www.formycon.com
Disclaimer:
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions which may be subject to variety of
risks and uncertainties. The results actually achieved by Formycon AG may
substantially differ from these forward-looking statements. Formycon AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments which differ from those anticipated.
---------------------------------------------------------------------
19.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Formycon AG
Fraunhoferstraße 145
82152 Planegg-Martinsried
Germany
Phone: 089 864667 100
Fax: 089 864667 110
Internet: www.formycon.com
ISIN: DE000A1EWVY8
WKN: A1EWVY
Listed: Regulated Unofficial Market in Berlin; Open Market (Entry
Standard) in Frankfurt
End of News DGAP News-Service
---------------------------------------------------------------------
359007 19.05.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Formycon AG ISIN: DE000A1EWVY8 können Sie bei EQS abrufen
Biotechnologie , A1EWVY , FYB , XETR:FYB